norfloxacin has been researched along with Hepato-Pulmonary Syndrome in 3 studies
Norfloxacin: A synthetic fluoroquinolone (FLUOROQUINOLONES) with broad-spectrum antibacterial activity against most gram-negative and gram-positive bacteria. Norfloxacin inhibits bacterial DNA GYRASE.
norfloxacin : A quinolinemonocarboxylic acid with broad-spectrum antibacterial activity against most gram-negative and gram-positive bacteria. Norfloxacin is bactericidal and its mode of action depends on blocking of bacterial DNA replication by binding itself to an enzyme called DNA gyrase.
| Excerpt | Relevance | Reference |
|---|---|---|
| " There was no major effect of norfloxacin on gas exchange in patients with hepatopulmonary syndrome." | 9.14 | Norfloxacin therapy for hepatopulmonary syndrome: a pilot randomized controlled trial. ( Bayoumi, AM; Faughnan, ME; Fowler, R; Gupta, S; Hutchison, S; Lilly, L, 2010) |
| "Hepatopulmonary syndrome was diagnosed after demonstration of the presence of a massive intrapulmonary shunt." | 1.31 | Novel presentation and approach to management of hepatopulmonary syndrome with use of antimicrobial agents. ( Añel, RM; Sheagren, JN, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (66.67) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gupta, S | 1 |
| Faughnan, ME | 1 |
| Lilly, L | 1 |
| Hutchison, S | 1 |
| Fowler, R | 1 |
| Bayoumi, AM | 1 |
| Rabiller, A | 1 |
| Nunes, H | 1 |
| Lebrec, D | 1 |
| Tazi, KA | 1 |
| Wartski, M | 1 |
| Dulmet, E | 1 |
| Libert, JM | 1 |
| Mougeot, C | 1 |
| Moreau, R | 1 |
| Mazmanian, M | 1 |
| Humbert, M | 1 |
| Hervé, P | 1 |
| Añel, RM | 1 |
| Sheagren, JN | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Pilot Study of Norfloxacin for Hepatopulmonary Syndrome[NCT00362752] | Phase 2 | 9 participants (Actual) | Interventional | 2006-10-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for norfloxacin and Hepato-Pulmonary Syndrome
| Article | Year |
|---|---|
Norfloxacin therapy for hepatopulmonary syndrome: a pilot randomized controlled trial.
Topics: Adult; Aged; Anti-Bacterial Agents; Cross-Over Studies; Female; Hepatopulmonary Syndrome; Humans; Ma | 2010 |
2 other studies available for norfloxacin and Hepato-Pulmonary Syndrome
| Article | Year |
|---|---|
Prevention of gram-negative translocation reduces the severity of hepatopulmonary syndrome.
Topics: Animals; Anti-Infective Agents; Antibiotic Prophylaxis; Bacterial Translocation; Common Bile Duct; D | 2002 |
Novel presentation and approach to management of hepatopulmonary syndrome with use of antimicrobial agents.
Topics: Adult; Anti-Infective Agents; Brain Abscess; Hepatopulmonary Syndrome; Humans; Male; Nitric Oxide; N | 2001 |